Melanoma is a global issue, with the incidence increasing worldwide. Despite great strides in the treatment of melanoma, vast differences still exist between countries and regions. In the United States, patient advocacy organizations, such as AIM at Melanoma, continuously push for access to medicines, regulatory improvements, and research, but in most other countries around the world, patient advocacy is still in its infancy.
AIM is the largest international melanoma foundation globally engaged and locally invested in advancing the battle against melanoma through innovative research, legislative reform, education, and patient and caregiver support in the United States and beyond. In 2014, AIM at Melanoma formed MI-PAC, a global coalition of advocacy organizations, to empower and engage committed patient advocates outside the United States. AIM hopes in this way to help create better outcomes for melanoma patients and the caregivers/families they represent, regardless of the environmental and political landscapes in which they operate.
This international coalition is composed of patient advocacy organizations whose mission is to educate patients and their caregivers/families about melanoma, to ensure access to clinical trials and approved drugs, to facilitate the approval process in their respective countries, and to raise awareness about prevention and early detection of the disease. Each organization is legally recognized, independently run, and active on social media.
MI-PAC includes representatives from Argentina, Australia and Tasmania, Brazil, Pan-Latin America, Canada, Ireland, Israel, Italy, France, Scotland, Eastern Europe, Spain, The United Kingdom, United States.
MI-PAC provides an environment for global patient advocates to acquire the tools and resources to successfully advocate on behalf of their melanoma communities. MI-PAC also provides advocates opportunities to network with Key Opinion Leaders and healthcare professionals, and to share the perspectives of patients and their caregivers/families with the international melanoma community.
MI-PAC participants meet twice yearly, at the Post-Chicago Melanoma/Skin Cancermeeting held in Munich and at the European Society for Medical Oncology (ESMO) meeting. These conferences enable the advocates to keep abreast of the ever-evolving melanoma environment so they can better serve patients, and their caregivers and family members.